Lauran Neergaard, Associated Press

The Food and Drug Administration’s decision Monday is part of a shift to treat fall COVID-19 vaccine updates much like getting a yearly flu shot.

The experiment at NYU Langone Health marks the longest a pig kidney has functioned in a person, albeit a deceased one, in another step toward animal-human transplants.

The common but scary respiratory virus fills U.S. hospitals with wheezing babies each fall.

After flu hit historically low levels during the COVID-19 pandemic, it may be poised for a comeback. The main clue: A nasty flu season just ended in Australia.

The Food and Drug Administration on Wednesday authorized its first update to COVID-19 vaccines, and shots could begin within days.

U.S. regulators said Friday they are no longer considering authorizing a second COVID-19 booster shot for all adults under 50 this summer, focusing instead on revamped vaccines for the fall that will target the newest viral subvariants.

Between waning immunity and a relentless barrage of coronavirus variants, protection against infections has dropped markedly.

Earlier this week, the Food and Drug Administration authorized Pfizer’s kid-sized booster, to be offered at least five months after the youngsters’ last shot.

The Centers for Disease Control and Prevention must decide whether to formally recommend the booster for this age group. The CDC’s scientific advisers are scheduled to meet on Thursday.

David Bennett of Maryland, 57, had otherwise faced certain death — ineligible for a human heart transplant, bedridden and on life support, and out of other options.

Immunocompromised Americans at high risk from COVID-19 are now allowed to get a third vaccination in hopes of better protection.

Health authorities are trying to determine whether heart inflammation that can occur along with many types of infections could also be a rare side effect in teens and young adults after the second dose of COVID-19 vaccine.

Moderna aims to be next in line to offer vaccine to younger teens, saying it will submit its data to the FDA and other global regulators early next month.

Shots could begin as soon as a federal vaccine advisory committee issues recommendations for using the two-dose vaccine in 12- to 15-year-olds, expected Wednesday.